Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)

Abstract

Background There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. Objective Develop evidence-based, rapid, living guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. Methods In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise to regularly review the evidence and make recommendations about the treatment and management of persons with COVID-19. The process used a living guideline approach and followed a rapid recommendation development checklist. The panel prioritized questions and outcomes. A systematic review of the peer-reviewed and grey literature was conducted at regular intervals. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Results Based on the most recent search conducted on May 31, 2022, the IDSA guideline panel has made 30 recommendations for the treatment and management of the following groups/populations: pre- and post-exposure prophylaxis, ambulatory with mild-to-moderate disease, hospitalized with mild-to-moderate, severe but not critical, and critical disease. As these are living guidelines, the most recent recommendations can be found online at: https://idsociety.org/COVID19guidelines. Conclusions At the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials. Since then, many trials were done which provided much needed evidence for COVID-19 therapies. There still remain many unanswered questions as the pandemic evolved which we hope future trials can answer.

Evaluating clinical effectiveness of SARS‐CoV‐2 vaccine in solid organ transplant recipients: A propensity score matched analysis

“…Prior studies have reported a high mortality rate of SOTRs with COVID‐19 in the prevaccine era, ranging from 18% to 24% 1–4 . The lower death rate in our not fully vaccinated group may have been due to the inclusion of partially vaccinated patients in this group as well as improved treatments for COVID‐19 including postexposure monoclonal antibodies and anti‐inflammatory therapies such as tocilizumab and baricitinib 25 . Importantly, all COVID‐19‐related deaths in our study were in unvaccinated patients.…”

Hospital-acquired infections in patients hospitalized with COVID-19: First report from Taiwan

“…18 However, several guidelines for COVID-19 treatment suggest that antibiotics should not be routinely prescribed. [19][20][21] From the real-world clinical settings in Taiwan, COVID-19 patients often present as febrile with respiratory symptoms, such as fever, dry cough, dyspnea, and associated chest X-ray changes, as reported in other countries. 10,22,23 It is difficult for clinicians to differentiate COVID-19 patients with and without concurrent bacterial infections at admission.…”

Clinical Profile and Outcomes of Diabetic Ketoacidosis during the COVID-19 Pandemic in North India

“…The diagnosis, defining severity, and management of COVID-19 was modified according to the available recommendations by the Infectious Diseases Society of America and the National Institutes of Health during the pandemic. 15,16 All patients were followed throughout their hospital stay. Outcomes were recorded as the time required for resolution of DKA, in-hospital death or survival, and length of hospital stay (days).…”